Use of a ppar-delta agonist in the treatment of fatty acid oxidation disorders (faod)
AssigneeReneo Pharmaceuticals, Inc.
InventorsColin O'CARROLL, Niall O'DONNELL, Lynn PURKINS, Alex DORENBAUM
Life of this patent
Estimating the term…
Abstract
Described herein is the use of PPARδ agonists in the treatment of fatty acid oxidation disorders.
Claims68
A method for treating a fatty acid oxidation disorder (FAOD) in a mammal comprising administering to the mammal with a FAOD a peroxisome proliferator-activated receptor delta (PPARδ) agonist compound.
A method for treating a fatty acid oxidation disorder (FAOD) in a mammal comprising administering to the mammal with a FAOD a peroxisome proliferator-activated receptor delta (PPARδ) agonist compound, wherein the PPARδ agonist compound is (E)-[4-[3-(4-fluorophenyl)-3-[4-[3-(morpholin-4-yl)propynyl]phenyl]allyloxy]-2-methyl-phenoxy]acetic acid, or a pharmaceutically acceptable salt thereof.
A method for measuring whole-body fatty acid oxidation in a human with a fatty acid oxidation disorder (FAOD) comprising:
- feeding the human with a fatty acid oxidation disorder (FAOD) a meal comprising 13C-enriched fatty acids and measuring the amount of exhaled 13CO2 from the human, wherein the human with a fatty acid oxidation disorder (FAOD) is undergoing treatment with a PPARδ agonist compound.
A method for measuring changes in whole-body fatty acid oxidation in a human with a fatty acid oxidation disorder (FAOD) comprising the steps of:
- 1) providing a meal enriched with a 13C labeled fatty acid;
- 2) administering to the human a PPARδ agonist compound, or a pharmaceutically acceptable salt thereof;
- and
- 3) collecting breath samples from the human at regular intervals and measuring for the content of 13CO2 in the breath samples.
Dependencies are inferred from the claim text.